Price range: $44.00 through $74.00 / 10 Vials
Selank is a synthetic heptapeptide and a powerful derivative of the naturally occurring tetrapeptide Tuftsin. It is widely recognized in neurobiology research for its dual-action as an anxiolytic (anti-anxiety) and a nootropic (cognitive enhancer). Unlike traditional sedatives, Selank helps balance the central nervous system, reducing emotional tension while simultaneously improving mental clarity, focus, and memory retention.
Amino Acid Sequence
Thr-Lys-Pro-Arg-Pro-Gly-Pro
Molecular Formula
$C_{33}H_{57}N_{11}O_{9}$
Molecular Weight
751.9 g/mol
PubChem CID
11765600
CAS Number
129954-34-3
Vial Size
3ml (or standard 2ml/5ml vials)
Contents
Lyophilized powder, white/off-white color
| Size | 10mg, 5mg |
|---|---|
| Mechanism of Action | GABAergic Modulation: Selank enhances the inhibitory neurotransmitter GABA (Gamma-Aminobutyric Acid) by modulating its receptors, which helps quiet the overactive nervous system during stress. Enkephalin Stabilization: It inhibits the enzymes that break down Enkephalins (natural "feel-good" peptides in the brain), effectively prolonging their calming and pain-relieving effects. BDNF Regulation: Research suggests Selank can increase the expression of Brain-Derived Neurotrophic Factor (BDNF), a key protein involved in the survival and growth of neurons. Immune-Brain Axis: Due to its Tuftsin-derived structure, it also influences the immune system by modulating interleukin levels, helping the body maintain homeostasis during periods of high physiological stress. |
| Storage & handling | Storage:Store the lyophilized vial in a cool, dry area protected from direct sunlight. |
All products on this site are for laboratory research, development, or analytical use only; they are NOT FOR HUMAN CONSUMPTION, medical, diagnostic, cosmetic, or veterinary applications.
These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat, or prevent any disease. Genixpep is not a compounding or outsourcing facility under sections 503A/503B of the FD&C Act.
